elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Fludarabine
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Fludarabine
RIS
0.001
(Research Intensity Score)
Papers
163
Top papers
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
2022 · 239 citations
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
2021 · 337 citations
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
2019 · 743 citations
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
2021 · 189 citations
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia
2022 · 97 citations
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
2021 · 80 citations
Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)
2021 · 77 citations
FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.
2024 · 18 citations
Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma
2024 · 12 citations
Newest papers
Radioimmunotherapy as a targeted strategy of reduced-intensity conditioning for allogeneic transplantation in leukemia
2026
A phase I clinical trial of autologous gamma delta T cells genetically engineered with a chimeric receptor to target the prostate stem cell antigen in patients with metastatic castration-resistant prostate cancer.
2026
Engineering a novel palladium@copper metal organic frameworks-functionalized nitrogen-doped MWCNTs for molecular-imprinted electrochemical sensing of fludarabine
2025 · 5 citations
Reduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507
2025 · 3 citations
A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma
2025 · 3 citations
Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）
2025 · 2 citations
BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease
2025 · 2 citations
CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma
2025 · 1 citations
First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study
2025 · 1 citations
Browse all papers →
Fludarabine's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Fludarabine's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link